Environmental

ASND’s high R&D intensity supports lower direct operating emissions than manufacturing peers, but the company’s environmental profile remains less disclosed than larger diversified healthcare peers.

The absence of reported capital-intensive production assets reduces exposure to energy and water risks versus pharma manufacturers, yet peer comparability is limited by sparse sustainability disclosure.

Environmental materiality is mainly indirect through clinical development and supply-chain oversight, where ASND appears broadly aligned with mid-cap biotech peers rather than differentiated.

No Tier 1 evidence indicates major environmental controversies, but limited public metrics constrain confidence versus peers with more mature climate and resource reporting.

Social

ASND’s research-heavy model supports a highly skilled workforce and generally lower frontline safety exposure than peers with large manufacturing or field operations.

Stock-based compensation at 2.9% of revenue suggests more moderate employee dilution pressure than previously indicated, improving alignment relative to peers with heavier equity compensation.

The company’s social risk is concentrated in clinical trial conduct, patient safety, and data integrity, where biotech peers face similar scrutiny and ASND appears broadly comparable.

Limited public evidence of labor or product controversies supports a stronger relative social position than peers with recurring operational or patient-facing incidents.

Governance

Debt-to-equity of 0.31 and net debt-to-EBITDA of -4.6 indicate a much stronger balance sheet than many biotech peers, reducing governance sensitivity around financing discipline.

High R&D spending at 26.0% of revenue is consistent with development-stage biotech peers, but it also raises oversight demands on capital allocation and milestone execution.

Stock-based compensation remains material, which can align management with shareholders, yet it also heightens governance scrutiny versus peers with lower dilution.

No major governance controversy is evident in the provided data, but limited disclosure and elevated leverage keep ASND below stronger-governed peers with cleaner balance sheets.

Overall Score

ASND’s ESG profile is strongest on social factors and weaker on governance, with limited environmental disclosure preventing a higher relative score versus peers.

Score Driver: Governance Remains The Main Constraint, Though The Balance Sheet Has Improved Materially And Now Offsets Some Dilution And Capital-Allocation Concerns.